uniQure N.V.
Close on Oct 19, 2026
- Market cap
- $1.47B
- P/E (TTM)
- –
- Dividend yield
- –
About uniQure
Pharmaceutical Preparations, SIC 2834
uniQure is a biotechnology company that develops genomic medicines and adeno-associated virus-based gene therapies for individuals living with severe genetic and debilitating illnesses. Its pipeline of investigational clinical treatments targets central nervous system and metabolic disorders, including Huntington’s disease, refractory mesial temporal lobe epilepsy, Fabry disease, and amyotrophic lateral sclerosis. The company also developed etranacogene dezaparvovec for hemophilia B, which is commercialized globally by partner CSL Behring under the brand name HEMGENIX.
The company operates internationally, conducting clinical trials across the United States and Europe, and previously maintained manufacturing operations in Lexington, Massachusetts. It maintains corporate subsidiaries, including uniQure France SAS, and manages an intellectual property portfolio spanning jurisdictions such as the United States, Europe, Australia, Japan, and Canada. The provided report does not state the company's headquarters location.
Summary of the business section of uniQure's latest annual report, written by StockData.
Company profile
Company
- Legal name
- uniQure N.V.
- Headquarters
- Amsterdam, Netherlands
- Address
- Paasheuvelweg 25a 1105 BP
- Phone
- 1-339-970-7000
- Employees
- 221, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- KPMG Accountants N.V., Amstelveen, the Netherlands
Stock & identifiers
- Ticker
- QURE
- Exchange
- Nasdaq
- IPO date
- Feb 6, 2014
- Shares outstanding
- 69M, Jul 24, 2026
- Public float
- $764.80M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1590560
- CUSIP
- N90064101
- ISIN
- USN900641010
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Matthew C. Kapusta | CEO, Managing Director | 531,109 |
| Walid Abi-Saab | Chief Medical Officer | 168,235 |
| Jeannette Potts | Chief Legal Officer | 133,246 |
| Kylie O'Keefe | Chief Customer & Strat Officer | 108,864 |
| Christian Klemt | Chief Financial Officer | 238,581 |
| Jack Kaye | Director | 43,056 |
| Madhavan Balachandran | Director | 49,644 |
| Robert Gut | Director | 32,259 |
| Jeremy P. Springhorn | Director | 43,251 |
| Rachelle Suzanne Jacques | Director | 33,903 |
| David D. Meek | Director | 39,747 |
| Leonard E. Post | Director | 35,494 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Kapusta | $3.29M | $7.17M | $1.90M | $66 | $120 |
| FY2024 Mr. Kapusta | $3.08M | $9.94M | $1.52M | $48 | $90 |
| FY2023 Mr. Kapusta | $6.58M | -$1.40M | $2.67M | $19 | $92 |
| FY2022 Mr. Kapusta | $5.63M | $6.96M | $2.35M | $63 | $89 |
| FY2021 Mr. Kapusta | $5.10M | $1.56M | $2.34M | $57 | $99 |
| FY2020 Mr. Kapusta | $4.47M | -$7.34M | $2.28M | $50 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 221 employees, 126 of whom are based in The Netherlands, 83 in the U.S.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 23, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 29, 2019 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 6, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 6, 2014 | Name change | Name changed from uniQure B.V. to uniQure N.V. |
| Jan 31, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |